Icahn: Biotechs must merge with Big Pharma

Biogen Idec CEO Jim Mullen (photo) is no wilting violet. When no Big Pharma companies stepped up to the plate to offer him what he thought the company was worth, he spurned them as too timid. And now that Carl Icahn--the bane of corporate CEOs who have drawn his ire--has criticized the biotech for not doing enough to sell the company, Mullen's not backing up an inch. "Monday morning quarterbacking" is how he describes Icahn's complaint. Biogen did serious buyout reviews twice in a month, he says, and no serious offer was to be had. But that's not enough to appease Icahn. "I think a lot of these biotechs have to merge with Big Pharma," he said on CNBC. "This [Biogen Idec] is one of them."

- read the report from the Boston Globe

Related Articles:
Icahn aims for Biogen control. Report
Biogen CEO spells out interest in biotech buyout. Report
Biogen CEO: Pharma too wimpy to deal. Report
Biogen shares deflate as it gives up on sale. Report
Efficient drug programs demand partners, outsourcing. Report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.